文献速递乳腺癌

帕博西尼在激素受体阳性晚期乳腺癌中的成本效果

Cost-effectiveness of palbociclib in hormone receptor-positive advanced breast cancer.
PubMed 文献 · Ann Oncol · 2017-01-01

研究采用离散事件模拟模型,从社会视角比较帕博西尼联合内分泌治疗与内分泌治疗单药用于激素受体阳性晚期乳腺癌的成本效果。结果显示,在初治患者中每增加一个质量调整生命年需约768 498美元,既往内分泌治疗患者中约918 166美元;在每质量调整生命年10万美元的支付意愿阈值下,两组成本效果概率均为0%。

要点

  • 初治患者中帕博西尼联合来曲唑每增加一个质量调整生命年花费约768 498美元。
  • 既往内分泌治疗患者中帕博西尼联合氟维司群每增加一个质量调整生命年花费约918 166美元。
  • 在每质量调整生命年10万美元支付意愿阈值下,两组成本效果概率均为0%。

核心结论

  • 从社会视角看,在美国,无论患者既往是否接受过内分泌治疗,帕博西尼联合治疗与常规治疗相比都极不可能具有成本效果。

研究设计与样本

  • 研究采用离散事件模拟模型,模拟癌症进展时间,从社会视角比较转移性疾病不同治疗策略的终生临床获益和成本。
  • 按获批适应症,内分泌治疗初治患者被分配至帕博西尼联合来曲唑组或来曲唑单药组;既往接受过内分泌治疗的患者被分配至帕博西尼联合氟维司群组或氟维司群单药组。
  • 模型假设基于已发表的临床试验数据和其他同行评议研究,并进行了单因素和概率敏感性分析以评估结果对模型假设变化的稳健性。

主要发现

  • 在内分泌治疗初治患者中,帕博西尼联合来曲唑较来曲唑单药每增加一个质量调整生命年花费约768 498美元。
  • 在既往接受过内分泌治疗的患者中,帕博西尼联合氟维司群较氟维司群单药每增加一个质量调整生命年花费约918 166美元。
  • 敏感性分析显示,在每质量调整生命年10万美元的支付意愿阈值下,帕博西尼在两组患者中具有成本效果的概率均为0%。

关键数值与推荐

  • 在内分泌治疗初治患者中,帕博西尼联合来曲唑每增加一个质量调整生命年的成本为768 498美元。
  • 在既往接受过内分泌治疗的患者中,帕博西尼联合氟维司群每增加一个质量调整生命年的成本为918 166美元。
  • 在每质量调整生命年100 000美元的支付意愿阈值下,两组中帕博西尼具有成本效果的概率均为0%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Palbociclib (PAL), a novel small-molecule inhibitor of cyclin-dependent kinases 4 and 6 for the treatment of advanced breast cancer, has demonstrated significant efficacy in prolonging progression-free survival when added to existing therapies. Considering the high cost of PAL, we assessed cost-effectiveness of adding PAL to usual care in treatment of advanced breast cancer. METHODS: We developed a discrete event simulation model to simulate time to cancer progression and to compare life time clinical benefit and cost of alternative treatment strategies for patients with metastatic disease from societal perspective. Per approved indication, endocrine treatment naive patients were assigned to PAL plus letrozole (PAL + LET) or letrozole alone (LET). Patients with prior endocrine therapy were assigned to PAL plus fulvestrant (FUL) (PAL + FUL) or FUL alone. The model assumptions were informed based on published clinical trial data and other peer reviewed studies. We carried out one-way and probabilistic sensitivity analyses to assess the robustness of our results to the changes in model assumptions. RESULTS: In treatment-naive patients, the addition of PAL to LET cost an estimated $768 498 per additional quality-adjusted life-year (QALY) gained. The addition of PAL to FUL in patients with prior endocrine therapy cost an estimated $918 166 per QALY gained. Sensitivity analyses demonstrated adding PAL has a 0% chance of being cost-effectiveness in either patient groups at a willingness-to-pay threshold of $100 000 per QALY. CONCLUSION: From a societal perspective, PAL treatment of both patient groups (with and without prior endocrine therapy) is highly unlikely to be cost-effective compared with the usual care in the USA.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Mamiya H, Tahara RK, Tolaney SM, et al. Cost-effectiveness of palbociclib in hormone receptor-positive advanced breast cancer. Ann Oncol. 2017. PMID: 28472324. doi:10.1093/annonc/mdx201

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。